



Dear **EUBREAST Members, Associates, Supporters, and Friends,**

We are delighted that the EUBREAST NETWORK continues to grow thanks to the support of friends and colleagues like you. In 2024, we expect to have at least seven EUBREAST studies recruiting patients, a new webinar project in development and more exciting collaborations like those in 2023: the ICARO Study with the OPBC, the start of the MELODY Trial with iBRA-NET, CluBREAST webinars with SENATURK, as well as fundraisers like the Milan Marathon Charity Run.

Additionally, and more importantly, we would like to let our friends and colleagues who are living in regions of conflict know that you are in our thoughts, and it is also on your behalf that we remain firmly committed to our mission of bettering lives of people afflicted by breast cancer everywhere.

Chairmen: **Oreste D. Gentilini, EUBREAST ETS and Thorsten Kuehn, EUBREAST e.V.**



## CURRENT EUBREAST CLINICAL TRIALS AND RESEARCH

**EUBREAST 1** has recently implemented protocol amendment n.3; the most important change is that the recruitment period has been extended until December 2024. As of Oct 2023 n. 287 patients have been recruited. Data management and monitoring by the German Breast Group (GBG 104).



**EUBREAST 3/AXSANA** As of November, 2023 AXSANA has recruited an incredible 4982 patients from 24 countries and has 283 active study sites. The Steering Board Committee has recently voted on "AXSANaplus", a continuation of AXSANA with no recruitment limitation. Thanks to all who have participated.



**EUBREAST 4/MELODY** The study began in January 2023 and has already recruited nearly 400 patients. 40 study sites are open in 10 countries. Conducted in collaboration with iBRA-NET.



**EUBREAST 5/SerMa** Ethical approval was received in October, however due to three data protection issues an amendment was just submitted. Additional funding has been requested from German Cancer Aid. The REDCap submission is complete, reviewed by KKS. NCT registration is complete and the study is listed. Expected start date is in January, 2024 in Germany.



**EUBREAST 11/I-PREPARE** The trial is ready to enroll its first patient and the study app is available for download! Four European centers have already received EC approval and four more Italian centers are about to submit the study to their ECs. In total, 93 centers worldwide have shown interest in joining the project and we hope they will all soon be ready to enroll their first patients.



**EUBREAST 13/UEMS-EUBREAST Breast Care Survey** The analysis will be made based on 471 survey replies. We are grateful to all those who took the time to participate. In collaboration with The European Union of Medical Specialists (UEMS-Multidisciplinary Joint Committee Breast Care).




**OPBC 05-EUBREAST 14 -ICARO6** Nodal burden and nodal recurrence in patients with isolated tumor cells after neoadjuvant chemotherapy treated with axillary dissection or axillary radiation - we are proud that this project will be presented orally at SABCS 2023.



**EUBREAST 15/GraMaReg** This international multicenter register trial for patients with idiopathic granulomatous mastitis is planning to start recruitment in the second quarter of 2024. It will include retrospective and prospective phases of data documentation. The trial has applied for Ethical approval.

**EUBREAST 16/NEO-ACT** A randomized study to examine if physical exercise intervention during NACT can increase pCR rates in breast cancer. As of Nov, 2023, Sweden and Finland started recruiting with approximately 50 patients and the trial is preparing to open sites in Germany, Australia, Scotland and the UK.



The EUBREAST Network is committed to researching less extensive approaches to breast cancer surgery in order to improve the quality of life of affected patients.

EUBREAST ETS - Via Manzoni 38 - Milan, Italy - EUBREAST e.V. - Esslingen am Neckar, Germany  
Email [here](mailto:info@eubreast.org) if wish to unsubscribe to this newsletter



**PLEASE SUPPORT THE EUBREAST NETWORK**



## RECENT PUBLICATIONS

- Tauber et al [Controversies in axillary management of patients with breast cancer - updates for 2024](#), Current Opinion in Obstetrics and Gynecology, 2023 Sep: 10.1097/GCO.0000000000000916
- Kohlberg et al [Axillary surgery in the case of limited involved axillary lymph nodes](#), Gland Surgery, 2023 Jun 30;12(6):727-729.
- Weber et al [Uncertainties and controversies in axillary management of patients with breast cancer](#), Cancer Treatment Reviews 2023 Jun: 117:102556
- Paluchowski et al [Real de-escalation or escalation in disguise?](#), Breast, 2023 Jun; 69: 249-257
- Paluchowski et al [Axillary staging in node-positive breast cancer converting to node negativity through neoadjuvant chemotherapy: Current evidence and perspectives](#), SJS 2023 Jun: 112(2):117-125
- Hartmann et al [Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study - Breast Cancer Research and Treatment 2023 Sept: 10.1007/s10549-023-07100-0](#)

## EUBREAST AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM 2023

PROJECT	POSTER/PRESENTATION DESCRIPTION	SESSION INFO
EUBREAST 1/GBG 104	Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial	PO5-18-10 Posters Session 5
EUBREAST 3/AXSANA	An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)	PO4-19-04 Posters Session 4
MAGSEEDS - a subgroup analysis of EUBREAST 3/AXSANA	Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer	PO1-23-02 M Posters Session 1
Radar Reflectors - a subgroup analysis of EUBREAST 3/AXSANA	Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer	PO3-23-03 Posters Session 3
EUBREAST 4/MELODY	A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (NCT05559411)	PO4-18-12 Posters Session 4
EUBREAST 5/SerMa Pilot	Is there a possible link between macrophage-based immune response and age?	PO4-25-06 Posters Session 4
EUBREAST 11/I-PREPARE	International Prospective REgistry on Pre-pectorAl breast Reconstruction (NCT 05817175)	PO5-19-02 Posters Session 5
Neo-ACT/EUBREAST 16	Physical exercise during neoadjuvant chemotherapy for breast cancer as a tool to increase pathological complete response rates.	PO1-19-06 Posters Session 1
OPBC05/EUBREAST-14R/ICARO	Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection?	GS02-02 - 7 Dec Oral Presentation
SENOMAC - EUBREAST SUPPORTED	Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized trial	GS02-06 – 7 Dec Oral Presentation

Posters will be available on our website  
after the SABCS conference  
[Click here](#)

## THE EUBREAST NETWORK EDUCATIONAL PROGRAM



**THE EUBREAST NETWORK EDUCATIONAL PROGRAM**

Interdisciplinary Management of Breast Cancer Patients Treated with Primary Systemic Therapy: What Surgeons Need to Know

Main Program Sponsor  
**MSD**

Program Sponsor  
**oncotype dx**

Please remember to check out our Educational Program: **“Interdisciplinary Management of Breast Cancer Patients Treated with Primary Systemic Therapy: What Surgeons Need to Know,”** with Giuseppe Curigliano, Oreste Gentilini, Thorsten Kuehn, Orit Kaidar-Person, Petra Steyerova and Giuseppe Viale. You can register for the five free, CME-accredited modules from our website <https://www.eubreast.org/eubreast-educational-program-2023/>.

A heartfelt thanks to our Sponsors: to **MSD** -which uses the power of leading-edge science to save and improve lives around the world; bringing forward medicines and vaccines for the world’s most challenging diseases - for their unrestricted sponsorship, as well as to **Exact Sciences**, which seeks to eradicate cancer and the suffering it causes.



The EUBREAST Network is committed to researching less extensive approaches to breast cancer surgery in order to improve the quality of life of affected patients.

EUBREAST ETS - Via Manzoni 38 - Milan, Italy - EUBREAST e.V. - Esslingen am Neckar, Germany

Email [here](#) if wish to unsubscribe to this newsletter

**PLEASE SUPPORT THE EUBREAST NETWORK**







## NEW EXECUTIVE TEAM MEMBERS

Eduard-Alexandru Bonci, MD, PhD, has joined the EUBREAST Executive Team as our Social Media Medical Supervisor and has already made an amazing contribution. Eddie is from Transylvania, Romania. He studied medicine in Cluj-Napoca and obtained his PhD from Iuliu Hatieganu University of Medicine and Pharmacy. After a decade in Cluj-Napoca, Eddie decided to explore new breast cancer treatment methods and surgical techniques and is proud to be part of the Breast Unit Team and Champalimaud Clinical Centre and a member of the CINDERELLA Project. He's also working towards his BRESO certification. Eddie hopes to make an impact in surgical research, surgical oncology education, and mentorship in countries with limited resources.



Maria Luisa Gasparri has joined the EUBREAST Executive Team as our Educational Webinar Supervisor. We are excited about the new format she is developing; stay tuned! Prof. ML Gasparri, MD, PhD, is *Professore Titolare* at the University of the Italian Switzerland. She worked in the Breast Surgery Unit at San Raffaele Hospital in Milan until February 2020, when she moved to the Ente Ospedaliero Cantonale of Lugano and Centro di Senologia della Svizzera Italiana (CSSI) where she currently works as a Gynecologist and Breast Surgeon. She has published more than 110 peer reviewed papers and her scientific contributions have been awarded prizes from several societies, including the SPIGC, AIGE, AGUI, SGGG and ISGE. She is the PI/promoter and national coordinator for several international prospective trials, including four EUBREAST studies.

## EUBREAST 3/AXSANA - CALL FOR FOLLOW-UP DATA

### NOTICE FOR AXSANA PARTICIPANTS

We are quickly approaching 5,000 enrolled patients. Please remember to provide us with follow-up data as soon as possible!



For any questions about this process, please contact [info@eubreast.org](mailto:info@eubreast.org)


## CLUBREAST ONLINE JOURNAL

This year, EUBREAST has had the privilege to organize the CluBreast Online Journal together with SENATURK. Recently, "The Best of CluBreast" was featured on IBreastBook, thanks to Dr Yazan Masannat, and is further evidence of the importance of these inter-group and international collaborations.

The next CluBreast online journal report will be held on **19 December 2023** at **18.00 CET** with Dr Judy Boughey on "Local Recurrence After Breast-Conserving Therapy in Patients with Multiple Ipsilateral Breast Cancer: Results from ACOSOG Z11102 (Alliance)". **Please join us!**

<https://us06web.zoom.us/j/84165013443?pwd=IZfTcSvz5UQlW7SyApf4zii4B52u0a.1>

Meeting ID: 841 6501 3443 Passcode: CluBreast



## FUNDRAISING

EUBREAST ETS is thrilled to be participating in the **2024 Milan Marathon Charity Run**.

We will have eight teams with four people each (please contact us if you wish to participate) and we are running to support the **EUBREAST II (R)/I-PREPARE Clinical Trial**

For more details about this relay race:

<https://www.retedeldono.it/onp/eubreast> and on our website at <https://www.eubreast.org/eubreast-ets-milan-charity-marathon/>



The EUBREAST Network is committed to researching less extensive approaches to breast cancer surgery in order to improve the quality of life of affected patients.

EUBREAST ETS - Via Manzoni 38 - Milan, Italy - EUBREAST e.V. - Esslingen am Neckar, Germany  
Email [here](mailto:info@eubreast.org) if wish to unsubscribe to this newsletter



**PLEASE SUPPORT THE EUBREAST NETWORK**